Zimmer Biomet (ZBH) Projected to Post Earnings on Tuesday

Zimmer Biomet (NYSE:ZBH) is expected to post its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect Zimmer Biomet to post earnings of $2.38 per share and revenue of $2.2235 billion for the quarter. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 8:30 AM ET.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.74 EPS. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $86.17 on Tuesday. Zimmer Biomet has a 52 week low of $84.59 and a 52 week high of $114.44. The stock has a market capitalization of $17.08 billion, a PE ratio of 21.33, a PEG ratio of 2.22 and a beta of 0.62. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.39 and a current ratio of 2.43. The stock’s fifty day moving average is $90.86 and its 200-day moving average is $95.92.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 30th. Investors of record on Tuesday, December 30th were given a dividend of $0.24 per share. The ex-dividend date was Tuesday, December 30th. This represents a $0.96 annualized dividend and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is 23.76%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Canaccord Genuity Group dropped their target price on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research note on Monday, November 10th. UBS Group lowered their price target on shares of Zimmer Biomet from $88.00 to $86.00 and set a “sell” rating for the company in a report on Wednesday, January 28th. Citigroup reduced their price objective on Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating on the stock in a report on Thursday, December 11th. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Finally, Royal Bank Of Canada dropped their target price on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $107.24.

Institutional Trading of Zimmer Biomet

Large investors have recently made changes to their positions in the company. Headlands Technologies LLC bought a new position in Zimmer Biomet during the second quarter worth about $37,000. Mpwm Advisory Solutions LLC acquired a new stake in shares of Zimmer Biomet during the third quarter worth about $65,000. Palisade Asset Management LLC acquired a new stake in shares of Zimmer Biomet during the third quarter worth about $70,000. Caitong International Asset Management Co. Ltd raised its position in shares of Zimmer Biomet by 449.7% during the third quarter. Caitong International Asset Management Co. Ltd now owns 786 shares of the medical equipment provider’s stock worth $77,000 after purchasing an additional 643 shares during the period. Finally, Parallel Advisors LLC lifted its holdings in shares of Zimmer Biomet by 43.4% during the 3rd quarter. Parallel Advisors LLC now owns 895 shares of the medical equipment provider’s stock valued at $88,000 after purchasing an additional 271 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.